BioArctic saw the highest growth of 0.99% in patent filings in May and 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of BioArctic’s patent filings and grants. Buy the databook here.
BioArctic has been focused on protecting inventions in Israel(IL) with two publications in Q2 2024
The Israel(IL) Patent Office dominates the patent grants with nearly 100% of grants. The European Patent Office(EPO), United States(US), and Israel(IL) patent Office are among the top ten patent offices where BioArctic is filings its patents. Among the top granted patent authorities, BioArctic has 100% of its grants in Israel(IL).
Regeneron Pharmaceuticals and Immatics could be the strongest competitors for BioArctic
Patents related to rare diseases lead BioArctic's portfolio
BioArctic has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Parkinson's disease related patents lead BioArctic portfolio followed by alzheimer's disease, and atherosclerosis
BioArctic has highest number of patents in parkinson's disease followed by alzheimer's disease, atherosclerosis, tauopathies, and lysosomal storage disorder. For parkinson's disease, nearly 6% of patents were filed and 50% of patents were granted in Q2 2024.
For comprehensive analysis of BioArctic's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.